SGLT2 Inhibition in Combination With Diuretics in Heart Failure
Status:
Completed
Trial end date:
2019-01-09
Target enrollment:
Participant gender:
Summary
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind,
placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing
empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild Chronic Heart
Failure with left ventricular systolic dysfunction who are already on a loop diuretic. Renal
physiological testing will be performed at two points on each arm to assess the effect of
empagliflozin, on urinary volume, compared to placebo. The secondary outcomes are to assess
the effect of empagliflozin in addition to loop diuretics on natriuresis, to assess the
safety of add-on SGLT2 inhibitor therapy as measured by changes to serum creatinine and eGFR,
to assess effects of empagliflozin on urinary protein/creatinine ratio, albumin/creatinine
ratio and cystatin C when compared to placebo.